- $2.95m
- -$5.59m
- $9.14m
U.S. STOCKS ON THE MOVE-Arcus Biosciences, Staffing 360 Solutions, DHI Group
Brief: Aravive Announces Positive Initial Results From Phase 1B Portion Of The Phase1b/2 Study Of Avb-500 In Combination With Cabozantinib In Clear Cell Renal Carcinoma
Aravive surges on positive data from kidney cancer study
Brief: Aravive Announces Three New Appointments To Its Board Of Directors
Aravive Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aravive Reports Q1 Loss Per Share $0.44
Aravive Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Aravive Announces First Patient Dosed In Phase 3 Registrational Trial Evaluating Avb-500 In Patients With Platinum Resistant Ovarian Cancer
Brief: Aravive Reports Q4 2020 Financial Results
Brief: Aravive To Present Phase 1B Data Evaluating AVB-500 In Platinum Resistant Ovarian Cancer
U.S. STOCKS ON THE MOVE-GameStop, AnaptysBio Inc, Pluralsight, McAfee
Aravive: Rises after dosing first patient in early-stage kidney cancer study
Brief: Aravive Announces $21 Million Registered Direct Offering With Eshelman Ventures Priced At-The-Market
Brief: Aravive Says Ray Tabibiazar Will Be Stepping Down From Board Of Directors
U.S. RESEARCH ROUNDUP- American Woodmark, Comtech Telecommunications, Mohawk Group Holdings
Brief: Aravive Inc - Received Guidance From U.S FDA On Phase 3 Trial Design For Avb-500 In Platinum Resistant Ovarian Cancer
Brief: Aravive Inc Says Entered Into Collaboration And License Agreement With 3D Medicines Inc On November 6
U.S. RESEARCH ROUNDUP-Mattel, Obseva, Technipfmc
Brief: Aravive Reports Third Quarter 2020 Financial Results And Provides Corporate Updates